# US 2026/0116890 A1 · Anti-cancer nuclear hormone receptor-targeting compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0116890 A1
- Document ID: US20260116890A1
- Status: Published application
- Kind: A1
- Application number: 19/228,575
- Filed: 2025-06-04
- Published: 2026-04-30
- Earliest claimed: 2021-03-23
- Assignees: Nuvation Bio Inc.
- Applicants: Nuvation Bio Inc.
- Inventors: David HUNG; Jayakanth KANKANALA; Christopher Paul MILLER; Jeremy David PETTIGREW; Son Minh PHAM; Ihab S. DARWISH
- Web page: https://patentgrep.com/patent/US20260116890A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07D 471/14: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07J 43/003: {not condensed}
- C07J 73/005: {by nitrogen as hetero atom}
- C07J 73/008: {by two hetero atoms}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

## Claims

### Claim 1

A compound of Formula III, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof:
wherein:
B1 is a nuclear receptor-targeting epitope;
L1 is a covalent bond or a linking moiety; and
A1 is of Formula IA:
wherein:
Y is —CH2—;
Z is O;
R1, R2, R3 and R4 are each independently hydrogen, halo, cyano, nitro, —OR15, —SR15, —NR15R16, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R15, —C(═O)OR15, —OC(═O)R15, —C(═O)NR15R16, —NR15C(═O)R16, —NR15C(═O)OR16, —S(═O)1-2R15, —S(═O)1-2NR15R16, —NR15S(═O)1-2R16, —Si(R15)3, or —C═NOR15, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R1, R2, R3 and R4 are independently optionally substituted with one or more R10 as valency permits;
or R1 and R2 are taken together with the atoms to which they are attached to form a C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more R10 as valency permits;
or R2 and R3 are taken together with the atoms to which they are attached to form a C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more R10 as valency permits;
or R3 and R4 are taken together with the atoms to which they are attached to form a C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more R10 as valency permits;
each R10 is independently halo, cyano, nitro, —OR17, —SR17, —SF5, —NR17R18, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R17, —C(═O)OR17, —OC(═O)OR17, —OC(═O)R17, —C(═O)NR17R18, —OC(═O)NR17R18, —NR7C(═O)NR17R18, —S(═O)1-2R17, —S(═O)1-2NR17R18, —NR17S(═O)1-2R18, —NR17S(═O)1-2NR17R18, —NR17C(═O)R18, —NR17C(═O)OR18, —Si(R17)3, or —C═NOR17, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of R10 are independently optionally substituted with one or more halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; and
each R15 and R16 is independently hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each alkyl, alkenyl, alkynyl, or cycloalkyl is optionally independently substituted with oxo, halo, hydroxyl or amino as valency permits; or R15 and R16 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino; and
each R17 and R18 is independently hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally substituted with oxo, halo, hydroxyl or amino as valency permits: or R17 and R18 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino;
wherein one or more atoms of Formula IA (e.g., hydrogen, methyl, or hydroxy) is replaced by a direct covalent bond L1.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof wherein A1 is of Formula IB:
wherein:
R1 is hydrogen, —C═NOR15, or C1-6 alkyl optionally substituted with one or more R10;
R2 is hydrogen, C1-6 alkyl, —N(R17R18)2, —NO2, —C1-6 alkylene-O—C1-6 alkyl, or —C1-6 alkylene-N(R17R18)2; or
R1 and R2 are taken together with the atoms to which they are attached to form a C3-10 cycloalkyl optionally substituted with one or more R10;
R3 is hydrogen, hydroxy, halo, C1-6 alkyl, or —O—C1-6 alkyl;
R4 is hydrogen, halo, C1-6 alkyl, or —O—C1-6 alkyl; or
R3 and R4 together form a —O—CH2—O— or —O—CH2CH2—O—;
Y is a bond, —CH2—, or —CH2—CH2—; and
Z is a bond or O;
wherein one or more atoms in one of R1, R2, and R3 is replaced by a direct covalent bond to L1.

### Claim 4 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein one or more atoms (e.g., hydrogen, methyl, or hydroxy) in one of R1, R2, and R3 is replaced by a direct covalent bond to L1.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein A1 is derived from

### Claim 7 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein A1 is:
wherein the wavy bond refers to the point of connection to L1.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is of Formula HA:
wherein:
the wavy bond refers to the point of connection to L1;
R30 is hydrogen, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one to five R10 as valency permits;
R40 is hydrogen, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one to five R10 as valency permits;
each R50 is independently halo, cyano, nitro, —OR170, —SR170, —NR170R180, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl; wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl is independently optionally substituted with one to five halo, hydroxyl or amino as valency permits;
each R100 is independently oxo, halo, cyano, nitro, —OR170, —SR170, —SF5, —NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R170, —C(═O)OR170, —OC(═O)OR170, —OC(═O)R170, —C(═O)NR170R180, —OC(═O)NR170R180, —NR170C(═O)NR170R180, —S(═O)1-2R170, —S(═O)1-2NR170R180, —NR170S(═O)1-2R180, —NR170S(═O)1-2NR170R180, —NR170C(═O)R180, —NR170C(═O)OR180 or —C═NOR17, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl of R100 are independently optionally substituted with one or more halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; and
each R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino.

### Claim 10 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is of Formula IB:
wherein:
the wavy bond refers to the point of connection to L;
R60 is hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one to five R100 as valency permits;
R80 is hydrogen, hydroxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C1-12 alkoxy, C3-12 cycloalkyl is optionally independently substituted with one to five R100 as valency permits;
R81 is hydrogen, hydroxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C1-12 alkoxy, or C3-12 cycloalkyl is optionally independently substituted with one to five R100 as valency permits;
or R80 and R81 are taken together with the atom to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino;
each R100 is independently oxo, halo, cyano, nitro, —OR170, —SR170, —SF5, —NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R170, —C(═O)OR170, —OC(═O)OR170, —OC(═O)R170, —C(═O)NR170R180, —OC(═O)NR170R180, —NR170C(═O)NR170R180, —S(═O)1-2R170, —S(═O)1-2NR170R180, —NR170S(═O)1-2R180, —NR170S(═O)1-2NR170R180, —NR170C(═O)R180, —NR170C(═O)OR180 or —C═NOR17, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl of R100 are independently optionally substituted with one or more halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; and
each R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino.

### Claim 11 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is of Formula IC:
wherein:
the wavy bond refers to the point of connection to L1;
R60 is hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one to five R100 as valency permits;
each R100 is independently oxo, halo, cyano, nitro, —OR170, —SR170, —SF5, —NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, —C(═O)R170, —C(═O)OR170, —OC(═O)OR170, —OC(═O)R170, —C(═O)NR170R180, —OC(═O)NR170R180, —NR170C(═O)NR170R180, —S(═O)1-2R170, —S(═O)1-2NR170R180, —NR170S(═O)1-2R180, —NR170S(═O)1-2NR170R180, —NR170C(═O)R180, —NR170C(═O)OR180 or —C═NOR17, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl of R100 are independently optionally substituted with one or more halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; and
each R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino.

### Claim 12 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is of Formula ID:
wherein:
the wavy bond refers to the point of connection to L;
A″ and A′″ are each independently O or S;
Ra and Rb are each independently CH3 or CH2CH3; or Ra and Rb together with the atom to which they are attached form a C3-5 cycloalkyl, oxirane, oxetane or tetrahydrofuran;
B, B10, B2, B3, B′, B1′, B2′ and B3′ are each independently CRc or N;
each Rc is independently hydrogen, fluoro, CN, or methyl;
D is NH, O, S, CH2 or C═O;
X″ is CN, halo, or NO2;
Y″ is CH3, CH2Rd, CHF2, or CF3;
Rd is halo;
Z′″ is H, C1-2 alkyl, C2 alkenyl or NO2; or
X″ and Y″ together form a
wherein the broken lines indicate bonds to the ring;
or Y″ and Z′″ together form or a
wherein each is a single or double bond, and wherein the broken lines indicate bonds to the ring; and
Z′ is CH or N.

### Claim 13 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is of Formula HE:
wherein:
the wavy bond refers to the point of connection to L;
Q is
wherein bond a is attached to ring a and bond b is attached to ring b;
Ra and Rb are each independently —CH3 or —CH2CH3; or Ra and Rb together with the atom to which they are attached form a C3-5 cycloalkyl, oxiranyl, oxetanyl, or tetrahydrofuranyl;
A and A′ are each independently O or S;
E, E1, E2, and E3 are each independently CRc or N, and each Rc is independently hydrogen, halo, CN, or methyl;
E4 is CF, CH or N;
Q1 is a bond, CH2, C═O, or (C═O)NH;
Q2 is NH, O, S, CH2, NH(C═O), C(═O)NH, or C═O;
R44, R45 and R46 are each independently hydrogen, CN, or C1-2 alkyl;
t is 0, 1, 2, 3 or 4;
each Re is independently halo, cyano, C1-4 alkyl, or C1-4 haloalkyl;
R41 is halo, CN, or NO2;
R42 is halo, CH3, CH2F, CHF2, or CF3; or
R41 and R42 together form a
wherein the broken lines indicate bonds to
ring a;
R43 is hydrogen, halo, C1-2 alkyl, C2 alkenyl, NO2, CF3; or
R42 and R43 together form a
wherein each is a single or double bond, and wherein the broken lines indicate bonds to ring a.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein B1 is:
wherein the wavy bond refers to the point of connection to L1.

### Claim 16 (depends on 1)

The compound of claim 1, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, wherein L1 is of formula:
wherein:
each La is —NR110—, —O—, —S(O)0-2—, —NR110C(O)—, —C(O)NR110—, —NR110C(O)NR110—, —NR110S(O)2—, —S(O)2NR110—, —NR110S(O)2NR110—, —CR120═N—NR110—, —NR110—N═CR120—, —C(O)—, —OC(O)—, —OC(O)O—, —C(O)O—, alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene, wherein each alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl;
each R110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;
each R120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl; and
q is an integer from 0 to 20.

### Claim 17 (depends on 1)

The compound of claim 1, wherein L1 is of the formula:
wherein:
each of Y10, Y20, Y30, and Y40 are independently a bond, —NR110—, —O—, —S(O)0-2—, —NR110C(O)—, —C(O)NR110—, —NR110C(O)NR110—, —NR110S(O)2—, —S(O)2NR110—, —NR110S(O)2NR110—, —CR120═N—NR110—, —NR110—N═CR120—, —C(O)—, —OC(O)—, —OC(O)O—, —(CH2CH2O)1-5—, —C(O)O—, alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, and heteroarylene; wherein each alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy;
each R110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;
each R120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;
each R130 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;
each R140 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;
each R150 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl; and
n′, n″, and m″ are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

### Claim 18 (depends on 1)

The compound of claim 1, wherein L1 is of the formula:
wherein each of Y10, Y20, and Y30 are independently a bond, optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene, optionally substituted heterocyclylene, —CR110R120—, —NR110—, —O—, —S(O)0-2—, —NR110C(O)—, —C(O)NR110—, —NR110S(O)2—, —S(O)2NR110—, —CR120═N—NR110—, —NR110—N═CR120—, —OC(O)—, or —C(O)—;
each R110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;
each R120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and
n′ and p′ are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

### Claim 19 (depends on 1)

The compound of claim 1, wherein L1 is of the formula:
wherein:
L2 is attached to ring b and L3 is attached to A;
L2 and L3 are each independently selected from a bond, CH2, CH2CH2, or C═O;
s is 1, 2, or 3; and
s′ is 0 or 1.

### Claim 20 (depends on 1)

The compound of claim 1, wherein the linking moiety is of the formula:
wherein the “*” and the wavy or dashed line represent a covalent bond.

### Claim 21

A compound selected from the compound as provided in Table 1 or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 23 (depends on 1)

A method of treating or preventing cancer, comprising administering an effective amount of the compound of claim 1, or a stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog or pharmaceutically acceptable salt thereof, to an individual in need thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer is liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, trophoblastic neoplasms, or prostatic carcinoma.

### Claim 25

(canceled)
